Talphera shares jump 20.92% intraday ahead of key Niyad trial data readout expected in 2026.

Talphera surged 20.92% intraday following news that its 2026 Niyad trial data readout—a pivotal catalyst for FDA approval, funding, and potential acquisition—has heightened investor anticipation. The article emphasized the trial’s critical role in determining regulatory pathways, triggering conditional financing, and enabling a possible corporate acquisition via CorMedix’s 60-day buyout window. While the news references future events (2026), the immediate market reaction suggests optimism over the trial’s strategic and financial implications, aligning with the stock’s upward momentum.